|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management
|
Aug 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Jun 2023
|
American Journal of Hematology
|
aplastic anemia
|
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Apr 2023
|
American Journal of Hematology
|
aplastic anemia
|
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
|
Nov 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab
|
Aug 2020
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
|
Apr 2016
|
Anemia
|
myelodysplastic syndromes (MDS)
|
